Financials

%ChgLast 12MReverse

	FY202312/31/2023	FY202412/31/2024	FY202512/31/2025	Last 12M03/31/2026
Cash and Cash Equivalents	88.5	71.1	41.3	31.7
Short Term Investments	-	-	-	-
Cash and Short Term Investments	88.5	71.1	41.3	31.7
Net Receivables	-	-	-	-
Inventory	1.5	-	-	-
Other Current Assets	1.0	0.2	0.2	0.5
Total Current Assets	92.2	74.5	45.6	36.7
Property, Plant & Equipment	-	-	-	-
Long Term Investments	1.7	-	-	-
Other Non-Current Assets	2.3	2.0	2.0	1.3
Total Non-Current Assets	4.0	2.0	2.0	1.3
Total Assets	96.3	76.4	47.6	37.9
Account Payables	0.8	0.7	4.3	2.6
Short Term Debt	-	-	-	-
Deferred Revenue	-	-	-	-
Other Current Liabilities	1.8	3.0	2.0	1.7
Total Current Liabilities	5.2	5.0	8.3	7.5
Long Term Debt	-	-	-	-
Other Non-Current Liabilities	-	-	-	-
Total Non-Current Liabilities	-	-	-	-
Total Liabilities	5.2	5.0	8.3	7.5
Common Stock	22.8	23.5	1.6	1.6
Retained Earnings	-186.3	-211.8	-246.6	-256.2
Total Stockholders Equity	91.0	71.5	39.4	30.5
Total Liabilities and Equity	96.3	76.4	47.6	37.9

Atossa Therapeutics, Inc.(ATOS US)